ERBB2 and gastric adenocarcinoma: While demonstration of these mutations is not required clinically, testing oesophageal and gastric adenocarcinomas for ERBB2 [human epidermal growth factor receptor 2 (HER2)] is recommended, as this influences treatment decisions.